215 related articles for article (PubMed ID: 17114003)
1. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo.
Verdoes M; Florea BI; Menendez-Benito V; Maynard CJ; Witte MD; van der Linden WA; van den Nieuwendijk AM; Hofmann T; Berkers CR; van Leeuwen FW; Groothuis TA; Leeuwenburgh MA; Ovaa H; Neefjes JJ; Filippov DV; van der Marel GA; Dantuma NP; Overkleeft HS
Chem Biol; 2006 Nov; 13(11):1217-26. PubMed ID: 17114003
[TBL] [Abstract][Full Text] [Related]
2. Profiling proteasome activity in tissue with fluorescent probes.
Berkers CR; van Leeuwen FW; Groothuis TA; Peperzak V; van Tilburg EW; Borst J; Neefjes JJ; Ovaa H
Mol Pharm; 2007; 4(5):739-48. PubMed ID: 17708652
[TBL] [Abstract][Full Text] [Related]
3. Proteasome activity profiling: a simple, robust and versatile method revealing subunit-selective inhibitors and cytoplasmic, defense-induced proteasome activities.
Gu C; Kolodziejek I; Misas-Villamil J; Shindo T; Colby T; Verdoes M; Richau KH; Schmidt J; Overkleeft HS; van der Hoorn RA
Plant J; 2010 Apr; 62(1):160-70. PubMed ID: 20042019
[TBL] [Abstract][Full Text] [Related]
4. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of new vinyl ester pseudotripeptide proteasome inhibitors.
Marastoni M; Baldisserotto A; Trapella C; Gavioli R; Tomatis R
Eur J Med Chem; 2006 Aug; 41(8):978-84. PubMed ID: 16713026
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence-based proteasome activity profiling.
de Jong A; Schuurman KG; Rodenko B; Ovaa H; Berkers CR
Methods Mol Biol; 2012; 803():183-204. PubMed ID: 22065226
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
[TBL] [Abstract][Full Text] [Related]
8. O-GlcNAc peptide epoxyketones are recognized by mammalian proteasomes.
Witte MD; Florea BI; Verdoes M; Adeyanju O; Van der Marel GA; Overkleeft HS
J Am Chem Soc; 2009 Sep; 131(34):12064-5. PubMed ID: 19658393
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides.
Baldisserotto A; Franceschini C; Scalambra F; Trapella C; Marastoni M; Sforza F; Gavioli R; Tomatis R
J Pept Sci; 2010 Nov; 16(11):659-63. PubMed ID: 20814885
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the distribution and dynamics of proteasomes in living cells.
Groothuis TA; Reits EA
Methods Enzymol; 2005; 399():549-63. PubMed ID: 16338381
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibitors of proteasome activity.
Gaczynska M; Osmulski PA
Methods Mol Biol; 2005; 301():3-22. PubMed ID: 15917622
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Zhou HJ; Aujay MA; Bennett MK; Dajee M; Demo SD; Fang Y; Ho MN; Jiang J; Kirk CJ; Laidig GJ; Lewis ER; Lu Y; Muchamuel T; Parlati F; Ring E; Shenk KD; Shields J; Shwonek PJ; Stanton T; Sun CM; Sylvain C; Woo TM; Yang J
J Med Chem; 2009 May; 52(9):3028-38. PubMed ID: 19348473
[TBL] [Abstract][Full Text] [Related]
14. Proteasome selectivity towards Michael acceptor containing oligopeptide-based inhibitors.
van der Linden WA; Geurink PP; Oskam C; van der Marel GA; Florea BI; Overkleeft HS
Org Biomol Chem; 2010 Apr; 8(8):1885-93. PubMed ID: 20449494
[TBL] [Abstract][Full Text] [Related]
15. A new fluorogenic peptide determines proteasome activity in single cells.
Urru SA; Veglianese P; De Luigi A; Fumagalli E; Erba E; Gonella Diaza R; Carrà A; Davoli E; Borsello T; Forloni G; Pengo N; Monzani E; Cascio P; Cenci S; Sitia R; Salmona M
J Med Chem; 2010 Oct; 53(20):7452-60. PubMed ID: 20883027
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Abe H; Momose I; Takahashi Y; Ikeda D; Akamatsu Y
Bioorg Med Chem Lett; 2010 Oct; 20(19):5839-42. PubMed ID: 20727746
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors; synthesis and activity of arecoline oxide tripeptide derivatives.
Marastoni M; McDonald J; Baldisserotto A; Canella A; De Risi C; Pollini GP; Tomatis R
Bioorg Med Chem Lett; 2004 Apr; 14(8):1965-8. PubMed ID: 15050638
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
19. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
